secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001104659-23-087375
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma amends exec comp; CEO base $717k, severance enhanced for change of control
--------------------------------------------------------------------------------

- CEO Meeker: base salary $717,254, bonus target 65%, severance 12 months (18 months +150% bonus on change in control).
- CFO Smith: base $480,000, bonus 40%, severance 9 months (12 months +100% bonus under change in control).
- CTO Shulman ($435,000) and EVP Chien ($473,000) receive similar amended terms.
- Severance conditioned on release of claims and continued compliance with restrictive covenants.
- 280G best-pay provision ensures after-tax maximization if excise tax applies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923087375/0001104659-23-087375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923087375/tm2322430d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer